Lexicon Pharmaceuticals advances three late-stage drug candidates with potential and risks

Lexicon Pharmaceuticals has three late-stage drug candidates, Zynquista, Inpefa, and pilavapadin, each with potential but also significant risks. Zynquista may be resubmitted to the FDA in early 2026 for Type 1 diabetes, but commercialization and reimbursement pose challenges. Inpefa's Phase III results for HCM are expected in Q1 2027, with solo commercialization being a concern. Pilavapadin's Phase III success depends on improved efficacy and differentiation, with partnership being vital. The company would need substantial additional funding to commercialize any of these assets independently.